Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 10,500 shares, a decrease of 23.9% from the August 31st total of 13,800 shares. Based on an average daily volume of 40,700 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company’s stock are short sold.

Theratechnologies Stock Performance

Shares of Theratechnologies stock traded up $0.06 during trading on Friday, hitting $1.25. 17,055 shares of the stock traded hands, compared to its average volume of 44,874. The stock has a market cap of $57.48 million, a P/E ratio of -6.37 and a beta of 1.41. The company has a fifty day moving average price of $1.33 and a two-hundred day moving average price of $1.34. Theratechnologies has a twelve month low of $0.88 and a twelve month high of $2.58.

Theratechnologies (NASDAQ:THTX) last issued its quarterly earnings data on Wednesday, July 10th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.04. The business had revenue of $22.02 million for the quarter. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. On average, equities research analysts expect that Theratechnologies will post -0.02 EPS for the current fiscal year.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.